History

Prof. Marek Radomski

Professor Marek Witold Radomski, M.D., Ph.D., currently, the vice-dean of research in College of Medicine at the University of Sasktchewan in Canada. Professor Radomski used to be the Chair of the Department of Pharmacology at Trinity College Dublin in Ireland. Professor Radomski graduated from the Jagiellonian University Medical College and obtained his M.D./Ph.D. in 1983. In 2002 he became Professor.

Professor Radomski is a long-time pharmacologist with years of experience in working both in academia and pharmaceutical industry in Poland (Jagiellonski University in Krakow and Polish Academy of Sciences in Warsaw), UK (Wellcome Research Laboratories in Beckenham), Spain (Lacer SA in Barcelona), Canada (University of Alberta in Edmonton) and USA (University of Texas in Houston. For the last 9 years, Professor Radomski has been the Professor of Pharmacology at Trinity College in Dublin. He has experience in academic teams management acquired in his own research team as well as the Centre for Cancer Research in the Department of Pharmacology at Trinity College Dublin. Professor Radomski has mentored more than 60 doctoral and post-doctoral graduates. He has also led research and development operations in pharmaceutical companies, such as Wellcome Research Laboratories (UK) and Lacer (Spain). He was Alberta Heritage Foundation for Medical Research scholar and scientist of the Canadian Institutes of Health Research. He has been appointed Doctor Honoris Causa by the Complutense University of Madrid and Fellow of Trinity College Dublin.

Professor Radomski also conducts audits of academic units in USA and Europe and has consulted pharmaceutical companies, such as Eli Lilly, Schwarz Pharma, Merck and Phytopharm. Currently, he is member of the Scientific and Medical Advisory Board at Solvotrin Therapeutics.

He is interested in platelet and vascular biology, pharmacological mediators including nitric oxide and matrix metalloproteinases, and most recently, in nanomedicine, nanopharmacology and nanotoxicology. Professor Radomski is a highly-cited pharmacologist (listed in www.isihighlycited.com, with more than 18,900 citations to date by Google Scholar).

From July 2013 to April 2016, Professor Marek Radomski was working in Kardio-Med Silesia as the Director for Science and Medicine. Currently, he is continuing his cooperation with Kardio-Med Silesia in research projects.